Effect of calcitonin and vitamin D in osteoporosis.

PubWeight™: 0.96‹?› | Rank: Top 15%

🔗 View Article (PMID 2505903)

Published in Calcif Tissue Int on September 01, 1989

Authors

G M Palmieri1, J A Pitcock, P Brown, J G Karas, L J Roen

Author Affiliations

1: Department of Medicine, University of Tennessee, Memphis.

Articles by these authors

(truncated to the top 100)

Missing value estimation methods for DNA microarrays. Bioinformatics (2001) 20.84

Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol (1999) 6.98

'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol (2000) 5.29

Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet (1974) 4.95

Human immunodeficiency virus integration in a cell-free system. J Virol (1990) 4.48

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet (1997) 4.43

Genetic control of natural variation in Arabidopsis glucosinolate accumulation. Plant Physiol (2001) 4.07

Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science (1992) 3.93

Community clinics for leg ulcers and impact on healing. BMJ (1992) 3.28

Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker's syndrome. Exp Neurol (1989) 3.00

Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev (1999) 2.96

Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci U S A (1999) 2.76

Bias inherent in retrospective waiting-time studies: experience from a vascular surgery waiting list. CMAJ (2000) 2.74

Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: any connection? BMJ (1995) 2.74

Transmissible familial Creutzfeldt-Jakob disease associated with five, seven, and eight extra octapeptide coding repeats in the PRNP gene. Proc Natl Acad Sci U S A (1991) 2.55

The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48

Further evidence for small-bodied hominins from the Late Pleistocene of Flores, Indonesia. Nature (2005) 2.47

Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci U S A (2000) 2.46

The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology (1987) 2.46

An extremely luminous X-ray outburst at the birth of a supernova. Nature (2008) 2.41

Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30

New clinical sign for orthostatic tremor. Lancet (1995) 2.25

Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants. FEBS Lett (2000) 2.22

Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22

Gastric cancer detection in gastric ulcer disease. Gut (1980) 2.20

Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man. J Pharmacol Exp Ther (1965) 2.16

Bovine spongiform encephalopathy [corrected] Creutzfeldt-Jakob disease. BMJ (1996) 2.15

Precautions in medical care of, and in handling materials from, patients with transmissible virus dementia (Creutzfeldt-Jakob disease). N Engl J Med (1977) 2.10

Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10

Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol (1986) 2.06

Diagnosis of Creutzfeldt-Jakob disease by Western blot identification of marker protein in human brain tissue. N Engl J Med (1986) 2.06

Supervised harvesting of expression trees. Genome Biol (2001) 2.02

Estimating cancer risk in relation to tritium exposure from routine operation of a nuclear-generating station in Pickering, Ontario. Chronic Dis Inj Can (2013) 1.97

Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases) Brain Pathol (1995) 1.86

Chiropractic care of children with nocturnal enuresis: a prospective outcome study. J Manipulative Physiol Ther (1991) 1.85

Assessment of aggression in psychiatric admissions: semistructured interview and case note survey. BMJ (2000) 1.85

Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease. Proc Natl Acad Sci U S A (1998) 1.85

Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Proc Natl Acad Sci U S A (1994) 1.85

Collaborative annotation of genes and proteins between UniProtKB/Swiss-Prot and dictyBase. Database (Oxford) (2009) 1.85

Typing prion isoforms. Nature (1997) 1.82

Expression of the gene defect in X-linked agammaglobulinemia. N Engl J Med (1986) 1.80

Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80

Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents. Proc Natl Acad Sci U S A (1999) 1.80

Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79

Clinical signs of early osteoarthritis: reproducibility and relation to x ray changes in 541 women in the general population. Ann Rheum Dis (1991) 1.79

Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 1.77

Kofi Annan describes new health fund for developing countries. BMJ (2001) 1.76

Ionophore toxicity in turkey breeders. Avian Dis (1983) 1.76

Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med (1985) 1.75

Acute movement disorders with bilateral basal ganglia lesions in uremia. Mov Disord (1998) 1.74

Campylobacter pylori infection in biopsy specimens of gastric antrum: laboratory diagnosis and estimation of sampling error. J Clin Pathol (1989) 1.74

A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology (1994) 1.70

Improvement of stiff-man syndrome with vigabatrin. Neurology (1997) 1.68

Cancer registries fear imminent collapse. BMJ (2000) 1.68

Beta amyloid gene duplication in Alzheimer's disease and karyotypically normal Down syndrome. Science (1987) 1.67

Illusory perceptions of space and time preserve cross-saccadic perceptual continuity. Nature (2001) 1.64

Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathological description. Ann Neurol (1994) 1.64

[Creutzfeldt Jakob disease. Recommended precautions for patient management and diagnostic procedures (author's transl)]. Rev Neurol (Paris) (1978) 1.61

Updating the Read Codes: user-interactive maintenance of a dynamic clinical vocabulary. J Am Med Inform Assoc (1997) 1.60

Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int (1999) 1.60

Incidence of Creutzfeldt-Jakob disease in Europe in 1993. Lancet (1994) 1.59

The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol (1991) 1.59

Spinal cord stimulation failed to relieve akinesia or restore locomotion in Parkinson disease. Neurology (2010) 1.58

Muscle force is generated by myosin heads stereospecifically attached to actin. Nature (1997) 1.56

Codon 178 mutation in ethnically diverse Creutzfeldt-Jakob disease families. Lancet (1991) 1.56

A new (two-repeat) octapeptide coding insert mutation in Creutzfeldt-Jakob disease. Neurology (1993) 1.55

EEG-EMG, MEG-EMG and EMG-EMG frequency analysis: physiological principles and clinical applications. Clin Neurophysiol (2002) 1.54

UK death rates from breast cancer fall by a third. BMJ (2000) 1.50

Chemical disinfection of Creutzfeldt-Jakob disease virus. N Engl J Med (1982) 1.48

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res (1998) 1.48

Creutzfeldt-Jacob disease associated with the PRNP codon 200Lys mutation: an analysis of 45 families. Eur J Epidemiol (1991) 1.48

The use of relaxation for the promotion of comfort and pain relief in persons with advanced cancer. Contemp Nurse (1994) 1.47

Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother (1993) 1.46

The question of clustering of Creutzfeldt-Jakob disease. Am J Epidemiol (1989) 1.46

Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease. Am J Hum Genet (1999) 1.46

Personality disorders, history of trauma, and posttraumatic stress disorder in subjects with anxiety disorders. Compr Psychiatry (2001) 1.45

Creutzfeldt-Jakob disease in France: III. Epidemiological study of 170 patients dying during the decade 1968--1977. Ann Neurol (1979) 1.45

Double-blind trial of carbenoxolone sodium capsules in duodenal ulcer therapy, based on endoscopic diagnosis and follow-up. Br Med J (1972) 1.44

Mutation in codon 200 of scrapie amyloid protein gene in two clusters of Creutzfeldt-Jakob disease in Slovakia. Lancet (1990) 1.44

Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44

Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A (1998) 1.43

Patient access to psychiatric records: the patients' view. J R Soc Med (1988) 1.43

Measles antibodies in the cerebrospinal fluid of patients with multiple sclerosis. Proc Soc Exp Biol Med (1971) 1.42

Deep brain stimulation can suppress pathological synchronisation in parkinsonian patients. J Neurol Neurosurg Psychiatry (2010) 1.42

Community cancer control in a rural, underserved population: the Appalachian Leadership Initiative on Cancer Project. J Health Care Poor Underserved (2001) 1.41

Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency. Proc Natl Acad Sci U S A (1988) 1.41

A rapid gas chromatographic method quantitating clozapine in human plasma or serum for the purpose of therapeutic monitoring. J Anal Toxicol (1996) 1.41

Endoscopic examination of the duodenal bulb: clinical evaluation of forward- and side-viewing fibreoptic systems in 200 cases. Gut (1972) 1.41

The clinical features and prognosis of chronic posthypoxic myoclonus. Mov Disord (1997) 1.41

Considerations on a group of 13 patients with Creutzfeldt-Jakob disease in the region of Parma (Italy) Eur J Epidemiol (1990) 1.40

Prostatic infarction associated with aortic and iliac aneurysm repair. J Urol (1990) 1.40

Collaboration between education and service. Results in a new patient program. MCN Am J Matern Child Nurs (1994) 1.39

VLA integrin expression in normal and diseased human kidney: how should we interpret immunohistochemical data? Nephron (1995) 1.38

Sarcoidosis: when and how should we treat? Br J Hosp Med (1995) 1.37

Are the after-effects of low-frequency rTMS on motor cortex excitability due to changes in the efficacy of cortical synapses? Clin Neurophysiol (2001) 1.34

Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype. J Infect Dis (2000) 1.34

Levodopa-induced modulation of subthalamic beta oscillations during self-paced movements in patients with Parkinson's disease. Eur J Neurosci (2005) 1.33

The association of GRB 060218 with a supernova and the evolution of the shock wave. Nature (2006) 1.32

Synthetic peptides corresponding to different mutated regions of the amyloid gene in familial Creutzfeldt-Jakob disease show enhanced in vitro formation of morphologically different amyloid fibrils. Proc Natl Acad Sci U S A (1993) 1.31

Outcomes of hand surgery. British Society for Surgery of the Hand. J Hand Surg Br (1995) 1.31